MaxCyte, Inc. (NASDAQ:MXCT) Receives $5.50 Average Target Price from Analysts

MaxCyte, Inc. (NASDAQ:MXCT) has received an average rating of “Hold” from the five brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $5.50.

MXCT has been the topic of several research analyst reports. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of MaxCyte in a report on Friday, April 24th. Finally, Craig Hallum dropped their price objective on MaxCyte from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, March 25th.

MaxCyte Stock Down 1.9%

MaxCyte stock opened at $1.04 on Friday. MaxCyte has a 52 week low of $0.64 and a 52 week high of $2.40. The business’s 50-day moving average price is $0.84 and its 200 day moving average price is $1.12. The firm has a market cap of $111.40 million, a price-to-earnings ratio of -2.81 and a beta of 1.37.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.06. MaxCyte had a negative return on equity of 20.03% and a negative net margin of 121.16%.The company had revenue of $6.22 million for the quarter, compared to analyst estimates of $7.28 million. Equities analysts expect that MaxCyte will post -0.3 EPS for the current year.

Institutional Trading of MaxCyte

Several institutional investors have recently bought and sold shares of MXCT. AQR Capital Management LLC grew its holdings in MaxCyte by 227.3% in the first quarter. AQR Capital Management LLC now owns 95,501 shares of the company’s stock valued at $261,000 after purchasing an additional 66,323 shares during the period. American Century Companies Inc. lifted its position in shares of MaxCyte by 10.6% in the second quarter. American Century Companies Inc. now owns 196,686 shares of the company’s stock valued at $429,000 after acquiring an additional 18,848 shares in the last quarter. Prudential Financial Inc. purchased a new position in shares of MaxCyte in the second quarter valued at approximately $26,000. Hsbc Holdings PLC lifted its position in shares of MaxCyte by 410.2% in the second quarter. Hsbc Holdings PLC now owns 273,218 shares of the company’s stock valued at $598,000 after acquiring an additional 219,662 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of MaxCyte in the second quarter valued at approximately $282,000. 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.